About neuren pharmaceuticals - NURPF
Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its products include Pipeline, Trofinetide, and NNZ-2591. The company was founded on December 17, 2001 and is headquartered in Camberwell, Australia.
NURPF At a Glance
Neuren Pharmaceuticals Ltd.
697 Burke Road
Camberwell, Victoria (VIC) 3124
| Phone | 61-3-9092-0480 | Revenue | 153.94M | |
| Industry | Pharmaceuticals: Generic | Net Income | 104.27M | |
| Sector | Health Technology | 2023 Sales Growth | 1,425.921% | |
| Fiscal Year-end | 12 / 2024 | Employees | N/A | |
| View SEC Filings |
NURPF Valuation
| P/E Current | 12.70 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 20.766 |
| Price to Sales Ratio | 14.473 |
| Price to Book Ratio | 15.486 |
| Price to Cash Flow Ratio | 18.152 |
| Enterprise Value to EBITDA | 15.668 |
| Enterprise Value to Sales | 13.46 |
| Total Debt to Enterprise Value | N/A |
NURPF Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 15.654 |
| Total Asset Turnover | 1.551 |
NURPF Liquidity
| Current Ratio | 5.78 |
| Quick Ratio | 5.78 |
| Cash Ratio | 5.344 |
NURPF Profitability
| Gross Margin | N/A |
| Operating Margin | 85.902 |
| Pretax Margin | 88.444 |
| Net Margin | 67.729 |
| Return on Assets | 105.03 |
| Return on Equity | 123.958 |
| Return on Total Capital | 74.463 |
| Return on Invested Capital | 123.958 |
NURPF Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |